Eli Lilly and Company (ETR:LLY)

Market Cap	537.61B
Revenue (ttm)	45.35B
Net Income (ttm)	11.75B
Shares Out	n/a
EPS (ttm)	13.02
PE Ratio	45.75
Forward PE	25.44
Dividend	5.29 (0.90%)
Ex-Dividend Date	Aug 15, 2025

Volume	4,456
Average Volume	5,929
Open	591.50
Previous Close	577.80
Day's Range	586.20 - 598.10
52-Week Range	535.80 - 888.30
Beta	0.44
RSI	40.92
Earnings Date	Aug 7, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD